Juan Fernando Vera
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$7.3MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $7.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 20, 2026 | NIH | SBIR Phase II A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | $665K | MARKER THERAPEUTICS, INC. |
| Aug 21, 2025 | NIH | SBIR Phase II A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX | $674K | MARKER THERAPEUTICS, INC. |
| Jul 25, 2025 | NIH | SBIR Phase II Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | $665K | MARKER THERAPEUTICS, INC. |
| Jul 16, 2025 | NIH | SBIR Phase II A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | $665K | MARKER THERAPEUTICS, INC. |
| May 7, 2025 | NIH | SBIR Phase II Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy | $1.3M | MARKER THERAPEUTICS, INC. |
| Sep 2, 2024 | NIH | SBIR Phase II Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | $665K | MARKER THERAPEUTICS, INC. |
| Aug 30, 2024 | NIH | SBIR Phase II A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX | $674K | MARKER THERAPEUTICS, INC. |
| Aug 8, 2024 | NIH | SBIR Phase II A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma | $665K | MARKER THERAPEUTICS, INC. |
| Jun 14, 2024 | NIH | SBIR Phase II Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy | $651K | MARKER THERAPEUTICS, INC. |
| Aug 8, 2023 | NIH | SBIR Phase II Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | $665K | MARKER THERAPEUTICS, INC. |
Peer ranks
Federal funding#132
Awards as PI#128
Patents#273
Companies
- MARKER THERAPEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.